New data on Bristol-Myers Squibb Co's melanoma drug Yervoy, including fresh results from an effort to combine it with another promising cancer immunotherapy, suggest it can improve treatment for patients with both advanced and slightly earlier stage disease, according to findings released on Monday. Yervoy, which takes natural brakes off the immune system to help it more effectively attack cancer, is approved to treat metastatic, or stage 4, melanoma - the deadliest form of skin cancer. During the annual American Society of Clinical Oncology meeting in Chicago, Bristol-Myers presented several studies on Yervoy and nivolumab, its experimental cancer immunotherapy from a highly promising class called PD-1 inhibitors, both as standalone treatments and in combination. In one late-stage study on Yervoy alone, the drug reduced the risk of melanoma recurrence by 25 percent following surgery compared with a placebo. via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment